Concepedia

Phase 2 study of nilotinib as third‐line therapy for patients with gastrointestinal stromal tumor

Akira Sawaki, Toshirou Nishida, Toshihiko Doi, Yasuhide Yamada, Yoshito Komatsu, Tatsuo Kanda, Yoshihiro Kakeji, Yusuke Onozawa, Makoto Yamasaki, Atsushi Ohtsu

Cancer · 2011 · 85 citations · 25 references

DOIFull text

Open access

Abstract

These results suggest that nilotinib is generally well tolerated and has encouraging antitumor activity in patients with GIST who failed both imatinib and sunitinib.

References

25

Gain-of-Function Mutations of c- <i>kit</i> in Human Gastrointestinal Stromal Tumors

Seiichi Hirota, Koji Isozaki, Y Moriyama et al. · Science · 1998 · 4.4K citations

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

George D. Demetri, Margaret von Mehren, Charles D. Blanke et al. · New England Journal of Medicine · 2002 · 4.4K citations · Full text

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett et al. · The Lancet · 2006 · 2.6K citations

, , +5

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Michael C. Heinrich, Christopher L. Corless, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 2.3K citations

<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors

Michael C. Heinrich, Christopher L. Corless, Anette Duensing et al. · Science · 2003 · 2.3K citations